ActiVin (Vitis vinifera)

ActiVin is a standardized grape seed extract (Vitis vinifera) concentrated in oligomeric proanthocyanidins (OPCs), particularly procyanidins, which neutralize reactive oxygen species by donating hydrogen atoms to free radicals. Its primary mechanism involves direct radical scavenging and upregulation of endogenous antioxidant defenses through Nrf2 pathway activation.

Origin & History

ActiVin is a branded extract derived from grape seeds (Vitis vinifera), standardized to contain high levels of oligomeric proanthocyanidins (OPCs) - specifically 54% dimeric, 13% trimeric, and 7% tetrameric OPCs. It is produced through solvent extraction of grape seeds, followed by fractionation, concentration via distillation, and spray-drying to create a powder with not more than 2% water-insoluble fraction.

Historical & Cultural Context

No historical or traditional medicinal uses of ActiVin or grape seed extracts were described in the available research. The product appears to be a modern standardized extract without documented traditional use.

Health Benefits

• Antioxidant activity demonstrated in vitro through DPPH radical scavenging (preliminary evidence only)
• Potential cellular protection based on general grape seed extract studies showing cytotoxicity to cancer cell lines (97.9% inhibition on HCT-116 cells at IC50 12.5 µg/mL - preliminary evidence)
• May support cardiovascular health through OPC content (no human clinical evidence available for ActiVin)
• Possible anti-inflammatory effects based on polyphenol composition (no direct clinical evidence)
• Cosmetic safety established by CIR review for topical use (not oral supplementation evidence)

How It Works

ActiVin's procyanidins and catechin monomers donate hydrogen atoms to neutralize DPPH and hydroxyl radicals, measured via in vitro scavenging assays. These OPCs also modulate the Nrf2-Keap1 pathway, upregulating cytoprotective enzymes including heme oxygenase-1 (HO-1) and superoxide dismutase (SOD). Cytotoxic activity against HCT-116 colorectal cancer cells (IC50 12.5 µg/mL, 97.9% inhibition) is hypothesized to involve caspase-mediated apoptosis and inhibition of NF-κB signaling, though human mechanistic data are absent.

Scientific Research

No human clinical trials, RCTs, or meta-analyses specifically on ActiVin were found in the research. The available evidence is limited to in vitro antioxidant assays and general grape seed extract studies, with no PubMed PMIDs provided for ActiVin-specific research.

Clinical Summary

Current evidence for ActiVin specifically is limited to in vitro assays; no published randomized controlled trials have been conducted on this branded ingredient in human subjects. The 97.9% HCT-116 cell inhibition at 12.5 µg/mL and DPPH radical scavenging data are preliminary, cell-culture findings that do not establish human efficacy. Broader grape seed extract research in humans includes small trials (n=24–61) showing modest reductions in LDL oxidation and blood pressure, but these cannot be directly extrapolated to ActiVin without bridging studies. Overall, the evidence base is rated preliminary to insufficient, requiring well-powered human RCTs before clinical claims can be substantiated.

Nutritional Profile

ActiVin is a standardized grape seed extract (Vitis vinifera) concentrate, not a whole food, so macronutrient content (fat, carbohydrate, protein) is negligible at typical supplemental doses (50–300 mg/day). Primary bioactive compounds are oligomeric proanthocyanidins (OPCs), standardized to a minimum of 95% polyphenols/OPCs by manufacturer specification — this is the defining characteristic of the ActiVin branded extract. Specific constituents include: procyanidin dimers (B1, B2, B3, B4), trimers, and higher oligomers; catechin and epicatechin monomers (estimated 5–15% of total polyphenol content); gallic acid esters of the above (e.g., epicatechin-3-O-gallate); and trace resveratrol (stilbene), though concentrations are not standardized in seed extract and are generally low (<0.1% of extract weight). No meaningful vitamin or mineral content is present at supplemental doses. Fiber content is absent in the extract form. Bioavailability: OPC monomers (catechin, epicatechin) demonstrate moderate oral bioavailability (~20–40% absorption in humans); larger oligomers (trimers and above) show substantially lower intestinal absorption and are partially metabolized by colonic microbiota into smaller phenolic acids (e.g., 3-hydroxyphenylpropionic acid, protocatechuic acid) which may contribute to systemic effects. Peak plasma concentrations of catechin/epicatechin typically occur 1–2 hours post-ingestion. The ActiVin brand is produced by Constellation Brands/IEV using a water-based extraction process, which preserves native OPC profiles without solvent residues, but specific lot-to-lot concentration data beyond the 95% polyphenol standardization is not publicly documented.

Preparation & Dosage

No clinically studied dosage ranges for ActiVin have been established in human trials. The product is standardized to contain 54% dimeric OPCs, 13% trimeric, and 7% tetrameric OPCs in powder form. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Vitamin C, Vitamin E, Resveratrol, Quercetin, Pine Bark Extract

Safety & Interactions

Grape seed extracts including standardized OPC products are generally well tolerated at doses of 100–300 mg/day in short-term human studies, with headache, dizziness, and mild GI upset reported infrequently. ActiVin may potentiate anticoagulant and antiplatelet drugs such as warfarin and aspirin by inhibiting platelet aggregation, increasing bleeding risk. It may also interact with CYP3A4-metabolized medications by modulating cytochrome P450 enzyme activity, potentially altering plasma drug levels. Safety in pregnancy, lactation, and pediatric populations has not been established, and use in these groups should be avoided without medical supervision.